BAXTER INTERNATIONAL INC acquired Gambro AB for SEK 26.5 billion total consideration (approximately $4.0 billion), including payoff of existing Gambro indebtedness, a transaction completed in September 2013, structured as all cash.
Gambro AB operates in Renal / dialysis, is based in Lund, Sweden (global operations). Gambro is a privately held global medical technology company based in Lund, Sweden, focused on developing, manufacturing and supplying dialysis products and therapies used in hemodialysis and continuous renal replacement therapy for patients with acute or chronic kidney disease.
The acquisition gives Baxter a comprehensive dialysis product portfolio, complements Baxter's global home dialysis offerings, and positions the company to better meet the evolving needs of the large and growing dialysis market by extending its portfolio in the hemodialysis segment.
Created a comprehensive, complementary global dialysis portfolio across home and in-center therapies in a large and growing market with more than two million patients globally on dialysis. Baxter expected the transaction to support accelerated sales and earnings growth over its long-range financial plan. Integrated into Baxter's Renal business
Baxter has a legacy of innovation in dialysis, including the development of peritoneal dialysis for the treatment of end-stage kidney disease patients in the home. This acquisition further strengthens our global dialysis offerings by extending our portfolio in the hemodialysis segment.Robert L. Parkinson, Jr., Chairman and CEO, Baxter
Both companies have a longstanding heritage in kidney care with innovative technologies and a dedication to saving, sustaining and improving the lives of patients worldwide.Guido Oelkers, President and CEO, Gambro
Advisory firms were not disclosed for this transaction.